{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0"},{"groupId":"OG001","value":"3.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1950"},{"groupId":"OG001","value":"1953"}],"units":"Participants"}],"description":"Cumulative incidence of arterial thrombotic events, as defined by CTCAE version 4.0 (grade ≥1 stroke or transient ischaemic attack; grade ≥2 acute coronary syndrome or cerebrovascular ischaemia; grade ≥3 myocardial infarction, peripheral ischaemia, or visceral arterial ischaemia; and grade ≥4 selected thromboembolic events \\[cerebrovascular event, arterial insufficiency\\]).","groups":[{"description":"Patients receive oral letrozole once daily for up to 5 years.\n\nLetrozole: Letrozole 2.5 mg taken orally once daily for 5 years","id":"OG000","title":"Group 2 Letrozole"},{"description":"Patients receive oral placebo once daily for up to 5 years.\n\nPlacebo: Placebo tablet taken orally once daily for 5 years","id":"OG001","title":"Group 1 Placebo"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"7 years","title":"Arterial Thrombotic Events","type":"SECONDARY","unitOfMeasure":"percentage of patients"}